Allarity Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Allarity Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2022 | ($2.27M) | Mar 8, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.23M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($24.52M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($11.90M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($16.06M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($26.65M) | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | ($6.62M) | May 17, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($12.61M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($27.24M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($17.13M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($34.46M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($26.56M) | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | ($8.32M) | May 17, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.60M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $6.10M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $7.10M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $6.93M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $14.20M | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | $4.22M | May 17, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.82M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($17.35M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($12.75M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($16.82M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($14.89M) | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | ($7.25M) | May 17, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $298.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $18.0K | Mar 8, 2024 |
| FY2021 | Dec 31, 2020 | $3.0K | May 17, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.26M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $22.65M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $11.86M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $14.54M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $49.63M | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | $33.40M | May 17, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.43M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $10.84M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $14.61M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $12.65M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $30.85M | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | $8.96M | May 17, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.83M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $11.81M | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | ($2.75M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | ($113.0K) | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $18.15M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $24.44M | Mar 13, 2023 |
| FY2021 | Dec 31, 2019 | $20.04M | May 17, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($130.20M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($118.97M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($94.45M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($82.55M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($66.49M) | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | ($39.84M) | May 17, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.69M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $19.53M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $166.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.03M | Mar 8, 2024 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $2.69M | Mar 31, 2025 |
| FY2022 | Dec 31, 2022 | $2.64M | Mar 13, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (15) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (6,031) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (3,093) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | (4) | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | (2) | May 17, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | (10) | Mar 8, 2024 |
| FY2023 | Dec 31, 2022 | (3,093) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | (4) | Mar 13, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 16.08M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 7.30M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 9,812 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 11,356 | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | 8.10M | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | 4.25M | May 17, 2022 |